ctDNA and TEP Levels in Colon Cancer
Determination of ctDNA and TEP Levels in Patients With Colon Cancer Receiving Neoadjuvant Systemic Therapy
This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic therapy followed by surgical resection.
Treatment will be given according to routine clinical practice and will depend on the biological characteristics of the tumor, including mismatch repair status. Participants will provide additional blood samples at predefined time points before, during, and after treatment and surgery. These samples will be used to analyze ctDNA and TEP and to assess whether changes in these biomarkers are associated with radiological response, pathological response, and disease-free outcomes.
Approximately 80 participants will be enrolled at the Institute of Oncology Ljubljana. Participants will not receive experimental drugs as part of this study.
研究概览
地位
条件
详细说明
This is a prospective interventional longitudinal cohort study of adult patients with histologically confirmed stage III colon adenocarcinoma who are planned to receive neoadjuvant systemic therapy followed by surgical resection with curative intent.
The study will evaluate the dynamics of circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) during neoadjuvant treatment and follow-up. Neoadjuvant systemic therapy will be selected according to routine clinical practice and tumor biology, including mismatch repair status. Patients with pMMR tumors may receive chemotherapy, while patients with dMMR tumors may receive immunotherapy, according to standard clinical decision-making.
The research intervention consists of additional peripheral venous blood sampling at predefined time points before treatment, during systemic treatment, before surgery, and after surgery. Blood samples will be analyzed for ctDNA and TEP-based biomarkers. Clinical, radiological, pathological, and follow-up data will be collected from routine medical documentation.
The primary objective is to determine whether the presence of ctDNA after completion of neoadjuvant systemic therapy is associated with pathological tumor response, defined as major pathological response (MPR), in patients with stage III colon cancer. Secondary and exploratory objectives include evaluation of the association between ctDNA, TEP profiles, radiological response, recurrence-free outcomes, and disease-free outcomes.
Approximately 80 participants will be enrolled. The study is academic and non-commercial. Participants will not receive experimental drugs as part of this study, and all therapeutic and diagnostic procedures will follow established clinical practice.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Tanja Mesti, MD
- 电话号码：+386 1 5879 287
- 邮箱：tmesti@onko-i.si
学习地点
-
-
-
Ljubljana、斯洛文尼亚、1000
- Institute of Oncology Ljubljana
-
接触：
- Klavdija Korošec
- 电话号码：+38631630065
- 邮箱：kkorosec@onko-i.si
-
接触：
- Tanja Mesti, MD
- 电话号码：+386 1 5879 287
- 邮箱：tmesti@onko-i.si
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age 18 years or older at the time of enrollment.
- Histologically confirmed adenocarcinoma of the colon.
- Stage III colon cancer, defined according to the applicable TNM classification based on clinical and imaging assessment.
- Confirmed mismatch repair (MMR) status, determined by immunohistochemistry and/or molecular methods.
- Planned neoadjuvant systemic therapy according to MMR status, followed by surgical resection with curative intent.
- ECOG performance status 0-2.
- Ability to understand the study and provide written informed consent.
Exclusion Criteria:
- Stage I, II, or IV colon cancer.
- Concurrent active malignant disease, except adequately treated non-melanoma skin cancer or carcinoma in situ.
- Severe comorbidities or medical conditions that prevent or substantially limit neoadjuvant systemic therapy or surgical resection.
- Known autoimmune disease requiring active immunosuppressive treatment in patients with dMMR tumors.
- Pregnancy or breastfeeding.
- Inability or unwillingness to provide written informed consent.
学习计划
研究是如何设计的？
设计细节
- 主要用途：诊断
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他：Biomarker Assessment Cohort
Participants with stage III colon cancer receiving neoadjuvant systemic therapy according to routine clinical practice will undergo additional peripheral venous blood sampling at predefined time points for ctDNA and TEP biomarker analysis.
|
Additional peripheral venous blood samples will be collected at predefined time points before treatment, during systemic treatment, before surgery, and after surgery.
Samples will be analyzed for circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP).
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Major Pathological Response in the Post-Neoadjuvant ctDNA Assessment
大体时间：From completion of neoadjuvant systemic therapy to pathological assessment after surgical resection, approximately 3 to 6 months.
|
Major pathological response will be assessed by histopathological evaluation of the surgical resection specimen after completion of neoadjuvant systemic therapy.
The unit of measure will be the percentage of participants with major pathological response.
ctDNA status after completion of neoadjuvant systemic therapy will be used as a pre-specified stratification variable in the statistical analysis.
|
From completion of neoadjuvant systemic therapy to pathological assessment after surgical resection, approximately 3 to 6 months.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Objective Radiological Response According to RECIST 1.1
大体时间：From baseline to preoperative radiological assessment, approximately 3 to 6 months.
|
Radiological response will be assessed according to RECIST version 1.1 using routine preoperative imaging.
Objective radiological response will include complete response and partial response.
The unit of measure will be the percentage of participants with objective radiological response.
ctDNA status after completion of neoadjuvant therapy will be used as a pre-specified stratification variable in the statistical analysis.
|
From baseline to preoperative radiological assessment, approximately 3 to 6 months.
|
|
Percentage of Participants Alive and Disease-Free at 12 Months After Surgical Resection
大体时间：12 months after surgical resection.
|
Disease-free status will be assessed using routine clinical, radiological, and follow-up documentation.
The outcome will be defined as being alive and without disease recurrence at 12 months after surgical resection.
The unit of measure will be the percentage of participants alive and disease-free at 12 months.
ctDNA status after completion of neoadjuvant therapy will be used as a pre-specified stratification variable in the statistical analysis.
|
12 months after surgical resection.
|
|
Percentage of Participants With Early Disease Recurrence Within 12 Months After Surgical Resection in the Postoperative ctDNA Assessment
大体时间：Up to 12 months after surgical resection.
|
Early disease recurrence will be assessed using routine clinical, radiological, and follow-up documentation.
The unit of measure will be the percentage of participants with disease recurrence within 12 months after surgical resection.
Postoperative ctDNA status will be used as a pre-specified stratification variable in the statistical analysis.
|
Up to 12 months after surgical resection.
|
|
Percentage of Participants With Early Disease Recurrence Within 12 Months After Surgical Resection in the Postoperative TEP Assessment
大体时间：Up to 12 months after surgical resection.
|
Early disease recurrence will be assessed using routine clinical, radiological, and follow-up documentation.
The unit of measure will be the percentage of participants with disease recurrence within 12 months after surgical resection.
Postoperative tumor-educated platelet status will be used as a pre-specified stratification variable in the statistical analysis.
|
Up to 12 months after surgical resection.
|
|
Percentage of Participants With Major Pathological Response in the Baseline ctDNA Assessment
大体时间：From baseline to pathological assessment after surgical resection, approximately 3 to 6 months.
|
Major pathological response will be assessed by histopathological evaluation of the surgical resection specimen.
The unit of measure will be the percentage of participants with major pathological response.
Baseline ctDNA status will be used as a pre-specified stratification variable in the statistical analysis.
|
From baseline to pathological assessment after surgical resection, approximately 3 to 6 months.
|
|
Percentage of Participants With Pathological Complete Response After Surgical Resection
大体时间：From baseline to pathological assessment after surgical resection, approximately 3 to 6 months.
|
Pathological complete response will be assessed by histopathological evaluation of the surgical resection specimen.
The unit of measure will be the percentage of participants with pathological complete response.
Baseline ctDNA status will be used as a pre-specified stratification variable in the statistical analysis.
|
From baseline to pathological assessment after surgical resection, approximately 3 to 6 months.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.